|
1
|
Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization.
|
Nat Methods
|
2008
|
2.88
|
|
2
|
Building a new conceptual framework for receptor heteromers.
|
Nat Chem Biol
|
2009
|
2.41
|
|
3
|
Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.
|
Nat Chem Biol
|
2010
|
2.15
|
|
4
|
Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis.
|
Mol Endocrinol
|
2002
|
1.76
|
|
5
|
Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy.
|
Proc Natl Acad Sci U S A
|
2012
|
1.57
|
|
6
|
Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
|
Prog Brain Res
|
2008
|
1.43
|
|
7
|
Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding.
|
Mol Pharmacol
|
2006
|
1.20
|
|
8
|
A fluorescent ligand-binding alternative using Tag-lite® technology.
|
J Biomol Screen
|
2010
|
1.13
|
|
9
|
D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation.
|
Anal Biochem
|
2006
|
1.11
|
|
10
|
The oligomeric state sets GABA(B) receptor signalling efficacy.
|
EMBO J
|
2011
|
1.05
|
|
11
|
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
|
J Med Chem
|
2007
|
1.02
|
|
12
|
Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus.
|
J Am Soc Nephrol
|
2009
|
0.99
|
|
13
|
The metabotropic glutamate receptor mGlu7 activates phospholipase C, translocates munc-13-1 protein, and potentiates glutamate release at cerebrocortical nerve terminals.
|
J Biol Chem
|
2010
|
0.95
|
|
14
|
The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation.
|
PLoS One
|
2009
|
0.94
|
|
15
|
Leukotriene BLT2 receptor monomers activate the G(i2) GTP-binding protein more efficiently than dimers.
|
J Biol Chem
|
2009
|
0.93
|
|
16
|
BRET and Time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues.
|
Front Endocrinol (Lausanne)
|
2012
|
0.92
|
|
17
|
Fluorescent ligands to investigate GPCR binding properties and oligomerization.
|
Biochem Soc Trans
|
2013
|
0.90
|
|
18
|
Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
|
J Med Chem
|
2002
|
0.87
|
|
19
|
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
|
J Med Chem
|
2012
|
0.85
|
|
20
|
Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane.
|
Mol Pharmacol
|
2008
|
0.85
|
|
21
|
Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors.
|
Mol Endocrinol
|
2006
|
0.83
|
|
22
|
Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion.
|
J Clin Endocrinol Metab
|
2010
|
0.83
|
|
23
|
Time resolved FRET strategy with fluorescent ligands to analyze receptor interactions in native tissues: application to GPCR oligomerization.
|
Methods Mol Biol
|
2011
|
0.80
|
|
24
|
Time-resolved FRET binding assay to investigate hetero-oligomer binding properties: proof of concept with dopamine D1/D3 heterodimer.
|
ACS Chem Biol
|
2014
|
0.80
|
|
25
|
Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
|
J Pept Sci
|
2005
|
0.80
|
|
26
|
Expression of human vasopressin and oxytocin receptors in Escherichia coli.
|
Prog Brain Res
|
2002
|
0.77
|
|
27
|
Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.
|
J Med Chem
|
2010
|
0.76
|
|
28
|
Time-resolved FRET strategy to screen GPCR ligand library.
|
Methods Mol Biol
|
2015
|
0.75
|
|
29
|
Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
|
J Med Chem
|
2015
|
0.75
|
|
30
|
From the Promiscuous Asenapine to Potent Fluorescent Ligands Acting at a Series of Aminergic G Protein Coupled Receptors.
|
J Med Chem
|
2017
|
0.75
|